comparemela.com

Latest Breaking News On - H score preclinical pipeline - Page 1 : comparemela.com

Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update

ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression. | March 29, 2023

Philippe bishopHerb crossJohn orwinXencor xmabAlex grayGates medical research instituteAtreca incExchange commissionXencor incMelinda gates medical research instituteChief executive officerH score preclinical pipelineRecent developmentsChief medicalPrivate securities litigation reform actAnnual report

Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update

29.03.2023 - ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression Phase 2 go/no-go decisions for ATRC-101 .

Xencor xmabPhilippe bishopAlex grayHerb crossJohn orwinXencor incGates medical research instituteMelinda gates medical research instituteAtreca incExchange commissionChief executive officerH score preclinical pipelineRecent developmentsChief medicalPrivate securities litigation reform actAnnual report

vimarsana © 2020. All Rights Reserved.